evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

901 questions · 1,073 findings · 138 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 166 · 15.5%GRADE not reported 310 · 28.9%Very low 213 · 19.9%Low 227 · 21.2%Moderate 132 · 12.3%High 25 · 2.3%

Highest vs lowest selenium exposure

Bladder cancer risk No. of participants: 19,009 (2 RCTs) · Participants in trials with low risk of bias

Highest showed no clear difference in bladder cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).

1 finding from 1 review

Highest vs lowest selenium exposure

Prostate cancer risk (13 studies) · Participants in trials with low risk of bias

Highest showed no clear difference in prostate cancer risk No. of participants: 18,942 (4 RCTs) compared with lowest selenium exposure (high certainty).

1 finding from 1 review

Highest vs lowest selenium exposure

Any cancer risk No. of participants: 76,239 (7 observational studies) · Participants in non experimental cohort studies on selenium and cancer

It is very uncertain whether highest changes any cancer risk No. of participants: 76,239 (7 observational studies) compared with lowest selenium exposure (very low certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

4 findings from 1 review
Show 1 more finding

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

High-intensity sweeteners other than stevia (aspartame, sucralose, saccharin) in food products vs Any comparator (dietary sugar, no treatment, or other sweetener)

Effects of non-stevia high-intensity sweeteners (aspartame, sucralose, saccharin) on cariogenic bacteria in dental plaque or saliva · healthy people

No eligible studies evaluated high-intensity sweeteners such as aspartame, sucralose, or saccharin for their effect on cariogenic bacteria.

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Mortality Median · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Progression/relapse · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Treatment‐related mortality · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

High feedback vs low feedback of routine prenatal ultrasound

Maternal anxiety · Pregnant women undergoing routine ultrasound during pregnancy

High feedback showed no clear difference in maternal anxiety ‐ throughout pregnancy compared with low feedback of routine prenatal ultrasound (low certainty).

2 findings from 1 review

High feedback vs low feedback of routine prenatal ultrasound

Cessation of alcohol · Pregnant women undergoing routine ultrasound during pregnancy

High feedback may leads to higher cessation of alcohol compared with low feedback of routine prenatal ultrasound (low certainty).

1 finding from 1 review